Key Highlights

  • IGC Pharma, Inc. Issued 2,226,475 shares to CEO Ram Mukunda at $0.27 per share, erasing $601,148 of owed amounts, including about $283,639 in personal cash advances.
  • Vice President and Principal Financial Officer Claudia Grimaldi received 2,048,378 shares at the same price, clearing $553,062 of obligations, including about $268,723 in cash advances.
  • The combined transactions eliminated $1,154,210 of outstanding debt, increasing shareholders’ equity without any cash outlay.

IGC Pharma, Inc. (NYSE American: IGC) disclosed that its chief executive officer, Ram Mukunda, and its vice president and principal financial officer, Claudia Grimaldi, each purchased newly issued common stock directly from the Company. The transactions convert personal advances totaling $1,154,210 into restricted shares and contribute to a stronger capital structure.

Debt‑to‑Equity Conversion

Under a private Stock Purchase Agreement, Mukunda acquired 2,226,475 shares of IGC Pharma common stock, each priced at $0.27. The issuance satisfied $601,148 of liabilities, of which roughly $283,639 represented cash advances previously made to the Company. The shares carry a par value of $0.0001 per share and are subject to resale restrictions.

Additional Executive Purchase

Grimaldi’s agreement mirrors the chief executive’s terms, granting her 2,048,378 shares at the same $0.27 price. This issuance satisfied $553,062 of outstanding obligations, including about $268,723 in cash advances she had extended to IGC Pharma.

Governance Review

Both transactions were reviewed and approved by the Company’s independent directors and audit committee. Directors with a conflict recused themselves for purposes of Rule 16b, preserving compliance with applicable exchange‑listed company rules. This reduction directly increased shareholders’ equity, reflecting a cleaner capital structure.

Regulatory Framework

No public offering, general solicitation, or underwriting fees were involved. The newly issued shares are classified as restricted securities and may not be sold or transferred except under registration or an applicable exemption such as Rule 144. The transactions are documented in a Stock Purchase Agreement, and represent a coordinated effort by IGC Pharma’s leadership to align personal investment with corporate performance.

FAQs

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.